Bisantrene (BioDeep_00000176735)

   

human metabolite blood metabolite


代谢物信息卡片


2-{2-[(10-{[2-(4,5-dihydro-1H-imidazol-2-yl)hydrazin-1-ylidene]methyl}anthracen-9-yl)methylidene]hydrazin-1-yl}-4,5-dihydro-1H-imidazole

化学式: C22H22N8 (398.1967332)
中文名称: 比生群
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5
InChI: InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)

描述信息

D000970 - Antineoplastic Agents

同义名列表

7 个代谢物同义名

2-{2-[(10-{[2-(4,5-dihydro-1H-imidazol-2-yl)hydrazin-1-ylidene]methyl}anthracen-9-yl)methylidene]hydrazin-1-yl}-4,5-dihydro-1H-imidazole; 9,10-Anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone; 9,10-Anthracendicarbaldehyde bis(2-imidazolin-2-ylhydrazone); Bisantrene dihydrochloride; Bisantrenum; Bisantrene; Bisantreno



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • T Leblanc, F Deméocq, G Leverger, A Baruchel, S Lemerle, J P Vannier, B Nelken, T Guillot, G Schaison. Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine. Medical and pediatric oncology. 1994; 22(2):119-24. doi: 10.1002/mpo.2950220211. [PMID: 8259097]
  • M L Scrobohaci, L Drouet, B Baudin. [Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy]. Nouvelle revue francaise d'hematologie. 1988; 30(1-2):109-14. doi: NULL. [PMID: 3290834]
  • P J Elson, R H Earhart, L K Kvols, R Spiegel, A M Keller, M S Kies, T E Davis, C Stevens, L Gumas, D L Trump. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. Cancer treatment reports. 1987 Mar; 71(3):331-2. doi: NULL. [PMID: 3815401]
  • C B Pratt, J A Sinkule, E Etcubanas, E C Douglass, D B Crom, K Choi, L Avery. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors. Investigational new drugs. 1986; 4(2):149-53. doi: 10.1007/bf00194594. [PMID: 3733375]
  • K Lu, N Savaraj, B S Yap, L G Feun, T Umsawasdi, T L Loo. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride. Cancer chemotherapy and pharmacology. 1986; 16(2):156-9. doi: 10.1007/bf00256167. [PMID: 3948302]
  • M Marty, C Ferme, C Gisselbrecht, H Guy, M J Clark, A Bancillon, M Boiron. Phase I study of bisantrene in acute nonlymphoblastic leukemia. Cancer treatment reports. 1985 Jun; 69(6):703-5. doi: NULL. [PMID: 4016773]
  • W K Evans, F A Shepherd, M E Blackstein, D Osoba, D Taylor. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma. Cancer treatment reports. 1985 Jun; 69(6):727-8. doi: NULL. [PMID: 4016779]
  • M Buck, J S Kovach. Blood and tissue concentrations of Bisantrene measured by a simple fluorometric assay. Cancer chemotherapy and pharmacology. 1985; 15(1):40-3. doi: 10.1007/bf00257292. [PMID: 4006048]
  • G R Weiss, M Hersh, J G Kuhn, T M Ludden, D D von Hoff, D L Kisner, T E Pirtle. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer. Cancer chemotherapy and pharmacology. 1985; 15(2):144-8. doi: 10.1007/bf00257525. [PMID: 4017163]
  • J S Kovach, M Buck, T Tsukamoto, A Odegaard, M M Lieber. Regional targeting of bisantrene by directed intravascular precipitation. Cancer chemotherapy and pharmacology. 1985; 15(3):192-5. doi: 10.1007/bf00263884. [PMID: 4053264]
  • Y M Peng, D S Alberts, T P Davis. In vivo and in vitro metabolism of the new anticancer drug bisantrene. Cancer chemotherapy and pharmacology. 1985; 14(1):15-20. doi: 10.1007/bf00552718. [PMID: 3965156]
  • H Gerad, D A Van Echo, M Donehower, R Pocelinko, P H Wiernik. Phase I-II trial of anthracenedicarboxaldehyde in patients with refractory adult acute leukemia. Cancer treatment reports. 1984 Mar; 68(3):535-7. doi: NULL. [PMID: 6584208]
  • R T Dorr, Y M Peng, D S Alberts. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote. Investigational new drugs. 1984; 2(4):351-7. doi: 10.1007/bf00171585. [PMID: 6096286]
  • G Powis, J S Kovach. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. Cancer research. 1983 Feb; 43(2):925-9. doi: NULL. [PMID: 6848203]
  • J G Kuhn, T M Ludden, J W Myers, D D Von Hoff. Characterization of the pharmacokinetics of bisantrene (NSC-337766). Investigational new drugs. 1983; 1(3):253-7. doi: 10.1007/bf00208899. [PMID: 6678875]
  • H Scher, S Schwartz, A Yagoda, R Watson, L Faye. Phase II trial of bisantrene for advanced hypernephroma. Cancer treatment reports. 1982 Aug; 66(8):1653-5. doi: NULL. [PMID: 7105056]
  • W H Wu, G Nicolau. Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals. Cancer treatment reports. 1982 May; 66(5):1173-85. doi: NULL. [PMID: 7083220]
  • R V Citarella, R E Wallace, K C Murdock, R B Angier, F E Durr, M Forbes. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Cancer research. 1982 Feb; 42(2):440-4. doi: NULL. [PMID: 7055799]
  • D D Von Hoff, J W Myers, J Kuhn, J F Sandbach, R Pocelinko, G Clark, C A Coltman. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942). Cancer research. 1981 Aug; 41(8):3118-21. doi: NULL. [PMID: 6265075]